Drug
Navenibart
Navenibart: highest development phase Phase 3, developed by United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| navenibart NCT07204938 | Phase 3 | Hereditary Angioedema (HAE) |
| navenibart NCT06842823 | Phase 3 | Hereditary Angioedema (HAE) |
Latest
No recent events.
Follow Navenibart on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.